Search for: "Price v. Federal Exp. Corp." Results 1 - 4 of 4
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Apr 2024, 10:08 am by admin
Initially, post-Daubert, federal courts were quick to excuse the absence of epidemiology for a novel claim. [read post]
20 Jun 2008, 8:07 am
– Marks & Clerk Biotechnology Report 2008: (IP finance), Pfizer and Daiichi-Sankyo’s bidding for Ranbaxy: (IP ThinkTank), (IAM), (Managing Intellectual Property), (GenericsWeb), Cutting Edge Information study reveals 53% of pharma patents approach expiration before litigation strategies are implemented: (Peter Zura's 271 Patent Blog), Quanta and agricultural biotechnology: (Holman’s Biotech IP Blog), Breakthough by WHO will give poor countries better access… [read post]